Table of Content

1. Key Insights

2. Region-Wise Market Share (%) Distribution of Hot Flashes Associated with Prostate Cancer Treatment in 2017

3. Region-Wise Market Share (%) Distribution of Hot Flashes Associated with Prostate Cancer Treatment in 2028

4. Disease Background and Overview: Hot Flashes Associated with Prostate Cancer Treatment
4.1. Introduction
4.2. Risk Factors for Prostate Cancer
4.3. Symptoms
4.4. Stages and Grades
4.5. Pathophysiology
4.6. Histopathology
4.7. Diagnosis

5. Androgen Deprived Therapy (ADT)-Associated Prostate Cancer Treatment
5.1. Treatment to lower testicular androgen levels
5.1.1. Orchiectomy
5.1.2. Luteinizing hormone-releasing hormone (LHRH) agonists
5.1.3. Luteinizing hormone-releasing hormone (LHRH) antagonists
5.2. Treatment to lower androgen levels from the adrenal glands
5.3. Drugs that stop androgens from working
5.3.1. Anti-androgens
5.3.2. Newer anti-androgens

6. Recognized Establishments

7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Cases of Hot Flashes Associated with Prostate Cancer Treatment in the 7MM

8. Country Wise-Epidemiology of Hot Flashes Associated with Prostate Cancer Treatment
8.1. United States
8.1.1. Assumptions and Rationale
8.1.2. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in the United States
8.1.3. Prostate Cancer by Stages in the United States
8.1.4. Progression from local and regional to advance stage in the United States
8.1.5. Hormone-sensitivity of Prostate cancer in Advance Stage in the United States
8.1.6. ADT use in Prostate Cancer in the United States
8.1.7. Rate of Hot Flashes Associated with Prostate Cancer Treatment in the United States
8.1.8. Hot Flashes by Severity in the United States
8.2. EU5 Countries
8.2.1. Assumptions and Rationale
8.3. Germany
8.3.1. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in Germany
8.3.2. Prostate Cancer by Stages in Germany
8.3.3. Progression from local and regional to advance stage in Germany
8.3.4. Hormone-sensitivity of Prostate cancer in Advance Stage in Germany
8.3.5. ADT use in Prostate Cancer in Germany
8.3.6. Rate of Hot Flashes Associated with Prostate Cancer Treatment in Germany
8.3.7. Hot Flashes by Severity in Germany
8.4. France
8.4.1. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in France
8.4.2. Prostate Cancer by Stages in France
8.4.3. Progression from local and regional to advance stage in France
8.4.4. Hormone-sensitivity of Prostate cancer in Advance Stage in France
8.4.5. ADT use in Prostate Cancer in France
8.4.6. Rate of Hot Flashes Associated with Prostate Cancer Treatment in France
8.4.7. Hot Flashes by Severity in France
8.5. Italy
8.5.1. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in Italy
8.5.2. Prostate Cancer by Stages in Italy
8.5.3. Progression from local and regional to advance stage in Italy
8.5.4. Hormone-sensitivity of Prostate cancer in Advance Stage in Italy
8.5.5. ADT use in Prostate Cancer in Italy
8.5.6. Rate of Hot Flashes Associated with Prostate Cancer Treatment in Italy
8.5.7. Hot Flashes by Severity in Italy
8.6. Spain
8.6.1. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in Spain
8.6.2. Prostate Cancer by Stages in Spain
8.6.3. Progression from local and regional to advance stage in Spain
8.6.4. Hormone-sensitivity of Prostate cancer in Advance Stage in Spain
8.6.5. ADT use in Prostate Cancer in Spain
8.6.6. Rate of Hot Flashes Associated with Prostate Cancer Treatment in Spain
8.6.7. Hot Flashes by Severity in Spain
8.7. United Kingdom
8.7.1. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in the United Kingdom
8.7.2. Prostate Cancer by Stages in the United Kingdom
8.7.3. Progression from local and regional to advance stage in the United Kingdom
8.7.4. Hormone-sensitivity of Prostate cancer in Advance Stage in the United Kingdom
8.7.5. ADT use in Prostate Cancer in the United Kingdom
8.7.6. Rate of Hot Flashes Associated with Prostate Cancer Treatment in the United Kingdom
8.7.7. Hot Flashes by Severity in the United Kingdom
8.8. Japan
8.8.1. Assumptions and Rationale
8.8.2. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in Japan
8.8.3. Prostate Cancer by Stages in Japan
8.8.4. Progression from local and regional to advance stage in Japan
8.8.5. Hormone-sensitivity of Prostate cancer in Advance Stage in Japan
8.8.6. ADT use in Prostate Cancer in Japan
8.8.7. Rate of Hot Flashes Associated with Prostate Cancer Treatment in Japan
8.8.8. Hot Flashes by Severity in Japan
8.8.9. Rate of Hot Flashes Associated with Prostate Cancer Treatment in Japan
8.8.10. Hot Flashes by Severity in Japan

9. Treatment of Hot Flashes in Men
9.1. Pharmacologic Treatment
9.1.1. Hormonal therapies
9.2. Nonhormonal therapies
9.3. Nonpharmacologic Therapies

10. Unmet Needs

11. Emerging Drug
11.1. Zuclomiphene citrate (Veru-944): Veru Pharma
11.1.1. Product Description
11.1.2. Other Developmental Activities
11.1.3. Clinical Development
11.1.4. Product Profile

12. What Experts Say?

13. Hot Flashes Associated with Prostate Cancer Treatment: 7 Major Market Analysis
13.1. Key Findings
13.2. Hot Flashes Associated with Prostate Cancer Treatment Market Overview at a Glance
13.2.1. Market Share (%) Distribution of Hot Flashes Associated with Prostate Cancer Treatment in 2017
13.2.2. Market Share (%) Distribution of Hot Flashes Associated with Prostate Cancer Treatment in 2028
13.3. Market Size of Hot Flashes Associated with Prostate Cancer Treatment in the 7MM Countries

14. The United States Market Outlook
14.1. United States
14.1.1. Total Market size of Hot Flashes Associated with Prostate Cancer Treatment
14.1.2. Market Size by Therapies

15. EU-5 Countries: Market Outlook
15.1. Germany
15.1.1. Total Market size of Hot Flashes Associated with Prostate Cancer Treatment
15.1.2. Market Size by Therapies

16. France
16.1.1. Total Market size of Hot Flashes Associated with Prostate Cancer Treatment
16.1.2. Market Size by Therapies

17. Italy
17.1.1. Total Market Size of Hot Flashes Associated with Prostate Cancer Treatment
17.1.2. Market Size by Therapies

18. Spain
18.1.1. Total Market Size of Hot Flashes Associated with Prostate Cancer Treatment
18.1.2. Market Size by Therapies

19. United Kingdom
19.1.1. Total Market Size of Hot Flashes Associated with Prostate Cancer Treatment
19.1.2. Market Size by Therapies

20. Japan: Market Outlook
20.1. Japan market Size
20.1.1. Total Market Size of Hot Flashes Associated with Prostate Cancer Treatment
20.1.2. Market Size by Therapies
21. Market Drivers
22. Market Barriers
23. Appendix
23.1. Report Methodology
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight



List of Figures


Figure 1: Risk Factors of Prostate Cancer
Figure 2: Staging for Prostate Cancer
Figure 3: TNM Staging System for Prostate Cancer
Figure 4: Illustration of Proposed Pathophysiologic Contributors to the Experience of Hot Flashes
Figure 5: Preliminary Tests
Figure 6: Confirmatory Tests
Figure 7: Imaging Tests
Figure 8: Diagnostic Algorithm of Prostate Cancer
Figure 9: Total Diagnosed Prevalent Patient Population of Hot Flashes Associated with Prostate Cancer Treatment in the 7MM Countries (2017–2028)
Figure 10: Diagnosed Prevalent Population of Prostate Cancer in the United States (2017–2028)
Figure 11: Prostate Cancer by Stages in the United States (2017–2028)
Figure 12: Progression from local and regional to advance stage in the United States (2017–2028)
Figure 13: Hormone-sensitivity of Prostate Cancer in Advance Stage in the United States (2017–2028)
Figure 14: ADT use in Prostate cancer in the United States (2017–2028)
Figure 15: Rate of Hot Flashes Associated with Prostate Cancer Treatment in the United States (2017–2028)
Figure 16: Hot Flashes by Severity in the United States (2017–2028)
Figure 17: Diagnosed Prevalent Population of Prostate Cancer in Germany (2017–2028)
Figure 18: Prostate Cancer by Stages in Germany (2017–2028)
Figure 19: Progression from local and regional to advance stage in Germany (2017–2028)
Figure 20: Hormone-sensitivity of Prostate Cancer in Advance Stage in Germany (2017–2028)
Figure 21: ADT use in Prostate cancer in Germany (2017–2028)
Figure 22: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Germany (2017–2028)
Figure 23: Hot Flashes by Severity in Germany (2017–2028)
Figure 24: Diagnosed Prevalent Population of Prostate Cancer in France (2017–2028)
Figure 25: Prostate Cancer by Stages in France (2017–2028)
Figure 26: Progression from local and regional to advance stage in France (2017–2028)
Figure 27: Hormone-sensitivity Prostate Cancer in Advance Stage in France (2017–2028)
Figure 28: ADT use in Prostate cancer in France (2017–2028)
Figure 29: Rate of Hot Flashes Associated with Prostate Cancer Treatment in France (2017–2028)
Figure 30: Hot Flashes by Severity in France (2017–2028)
Figure 31: Diagnosed Prevalent Population of Prostate Cancer in Italy (2017–2028)
Figure 32: Prostate Cancer by Stages in Italy (2017–2028)
Figure 33: Progression from local and regional to advance stage in Italy (2017–2028)
Figure 34: Hormone-sensitivity of Prostate Cancer in Advance Stage in Italy (2017–2028)
Figure 35: ADT use in Prostate cancer in Italy (2017–2028)
Figure 36: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Italy (2017–2028)
Figure 37: Hot Flashes by Severity in Italy (2017–2028)
Figure 38: Diagnosed Prevalent Population of Prostate Cancer in Spain (2017–2028)
Figure 39: Prostate Cancer by Stages in Spain (2017–2028)
Figure 40: Progression from local and regional to advance stage in Spain (2017–2028)
Figure 41: Hormone-sensitivity of Prostate Cancer in Advance Stage in Spain (2017–2028)
Figure 42: ADT use in Prostate cancer in Spain (2017–2028)
Figure 43: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Spain (2017–2028)
Figure 44: Hot Flashes by Severity in Spain (2017–2028)
Figure 45: Diagnosed Prevalent Population of Prostate Cancer in the United Kingdom (2017–2028)
Figure 46: Prostate Cancer by Stages in the United Kingdom (2017–2028)
Figure 47: Progression from local and regional to advance stage in the United Kingdom (2017–2028)
Figure 48: Hormone-sensitivity of Prostate Cancer in Advance Stage in the United Kingdom (2017–2028)
Figure 49: ADT use in Prostate cancer in the United Kingdom (2017–2028)
Figure 50: Rate of Hot Flashes Associated with Prostate Cancer Treatment in the United Kingdom (2017–2028)
Figure 51: Hot Flashes by Severity in the United Kingdom (2017–2028)
Figure 52: Diagnosed Prevalent Population of Prostate Cancer in Japan (2017–2028)
Figure 53: Prostate Cancer by Stages in Japan (2017–2028)
Figure 54: Progression from local and regional to advance stage in Japan (2017–2028)
Figure 55: Hormone-sensitivity of Prostate Cancer in Advance Stage in Japan (2017–2028)
Figure 56: ADT use in Prostate cancer in Japan (2017–2028)
Figure 57: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Japan (2017–2028)
Figure 58: Hot Flashes by Severity in Japan (2017–2028)
Figure 59: Treatment for Hot Flashes in men
Figure 60: Unmet Needs
Figure 61: 7 Major Market Size of Hot Flashes Associated with Prostate Cancer Treatment in USD Million (2017–2028)
Figure 62: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in the United States, USD Millions (2017–2028)
Figure 63: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in the US, in USD Million (2017–2028)
Figure 64: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Germany, USD Million (2017–2028)
Figure 65: Market Size of Hot Flashes Associated with Prostate Cancer Treatment by therapies, in Germany, in USD Million (2017–2028)
Figure 66: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in France, USD Million (2017–2028)
Figure 67: Market Size of Hot Flashes Associated with Prostate Cancer Treatment by therapies, in France, in USD Million (2017–2028)
Figure 68: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Italy, USD Million (2017–2028)
Figure 69: Market Size of Hot Flashes Associated with Prostate Cancer Treatment by therapies, in Italy, in USD Million (2017–2028)
Figure 70: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Spain, USD Million (2017–2028)
Figure 71: Market Size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in Spain, in USD Million (2017–2028)
Figure 72: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in the UK, USD Million (2017–2028)
Figure 73: Market Size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in the UK, in USD Million (2017–2028)
Figure 74: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Japan, USD Million (2017–2028)
Figure 75: Market Size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in Japan, in USD Million (2017–2028)
Figure 76: Market Drivers
Figure 77: Market Barriers

 

List of Tables


Table 1: Total Diagnosed Prevalent Population of Hot Flashes Associated with Prostate Cancer Treatment in the 7MM Countries (2017–2028)
Table 2: Diagnosed Prevalent Population of Prostate Cancer in the United States (2017–2028)
Table 3: Prostate Cancer by Stages in the United States (2017–2028)
Table 4: Progression from local and regional to advance stage in the United States (2017–2028)
Table 5: Hormone-sensitivity of Prostate Cancer in Advance Stage in the United States (2017–2028)
Table 6: ADT use in Prostate cancer in the United States (2017–2028)
Table 7: Rate of Hot Flashes Associated with Prostate Cancer Treatment in the United States (2017–2028)
Table 8: Hot Flashes by Severity in the United States (2017–2028)
Table 9: Diagnosed Prevalent Population of Prostate Cancer in Germany (2017–2028)
Table 10: Prostate Cancer by Stages in Germany (2017–2028)
Table 11: Progression from local and regional to advance stage in Germany (2017–2028)
Table 12: Hormone-sensitivity of Prostate Cancer in Advance Stage in Germany (2017–2028)
Table 13: ADT use in Prostate cancer in Germany (2017–2028)
Table 14: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Germany (2017–2028)
Table 15: Hot Flashes by Severity in Germany (2017–2028)
Table 16: Diagnosed Prevalent Population of Prostate Cancer in France (2017–2028)
Table 17: Prostate Cancer by Stages in France (2017–2028)
Table 18: Progression from local and regional to advance stage in France (2017–2028)
Table 19: Hormone-sensitivity Prostate Cancer in Advance Stage in France (2017–2028)
Table 20: ADT use in Prostate cancer in France (2017–2028)
Table 21: Rate of Hot Flashes Associated with Prostate Cancer Treatment in France (2017–2028)
Table 22: Hot Flashes by Severity in France (2017–2028)
Table 23: Diagnosed Prevalent Population of Prostate Cancer in Italy (2017–2028)
Table 24: Prostate Cancer by Stages in Italy (2017–2028)
Table 25: Progression from local and regional to advance stage in Italy (2017–2028)
Table 26: Hormone-sensitivity of Prostate Cancer in Advance Stage in Italy (2017–2028)
Table 27: ADT use in Prostate cancer in Italy (2017–2028)
Table 28: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Italy (2017–2028)
Table 29: Hot Flashes by Severity in Italy (2017–2028)
Table 30: Diagnosed Prevalent Population of Prostate Cancer in Spain (2017–2028)
Table 31: Prostate Cancer by Stages in Spain (2017–2028)
Table 32: Progression from local and regional to advance stage in Spain (2017–2028)
Table 33: Hormone-sensitivity of Prostate Cancer in Advance Stage in Spain (2017–2028)
Table 34: ADT use in Prostate cancer in Spain (2017–2028)
Table 35: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Spain (2017–2028)
Table 36: Hot Flashes by Severity in Spain (2017–2028)
Table 37: Diagnosed Prevalent Population of Prostate Cancer in the United Kingdom (2017–2028)
Table 38: Prostate Cancer by Stages in the United Kingdom (2017–2028)
Table 39: Progression from local and regional to advance stage in the United Kingdom (2017–2028)
Table 40: Hormone-sensitivity of Prostate Cancer in Advance Stage in the United Kingdom (2017–2028)
Table 41: ADT use in Prostate cancer in the United Kingdom (2017–2028)
Table 42: Rate of Hot Flashes Associated with Prostate Cancer Treatment in the United Kingdom (2017–2028)
Table 43: Hot Flashes by Severity in the United Kingdom (2017–2028)
Table 44: Diagnosed Prevalent Population of Prostate Cancer in Japan (2017–2028)
Table 45: Prostate Cancer by Stages in Japan (2017–2028)
Table 46: Progression from local and regional to advance stage in Japan (2017–2028)
Table 47: Hormone-sensitivity of Prostate Cancer in Advance Stage in Japan (2017–2028)
Table 48: ADT use in Prostate cancer in Japan (2017–2028)
Table 49: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Japan (2017–2028)
Table 50: Hot Flashes by Severity in Japan (2017–2028)
Table 51: Zuclomiphene citrate, Clinical Trial Description
Table 52: 7 Major Market Size of Hot Flashes Associated with Prostate Cancer Treatment in USD Million (2017–2028)
Table 53: United States Market Size of Hot Flashes Associated with Prostate Cancer Treatment, USD Million (2017–2028)
Table 54: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in the United States, in USD Million (2017–2028)
Table 55: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Germany, in USD Million (2017–2028)
Table 56: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in Germany, in USD Million (2017–2028)
Table 57: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in France, in USD Million (2017–2028)
Table 58: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in France, in USD Million (2017–2028)
Table 59: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Italy, in USD Million (2017–2028)
Table 60: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in Italy, in USD Million (2017–2028)
Table 61: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Spain, in USD Million (2017–2028)
Table 62: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in Spain, in USD Million (2017–2028)
Table 63: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in the UK, in USD Million (2017–2028)
Table 64: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in the UK, in USD Million (2017–2028)
Table 65: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Japan, in USD Million (2017–2028)
Table 66: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in Japan, in USD Million (2017–2028)